You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 14, 2024

VASOSTRICT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Vasostrict patents expire, and what generic alternatives are available?

Vasostrict is a drug marketed by Endo Operations and is included in one NDA. There are fourteen patents protecting this drug and four Paragraph IV challenges.

The generic ingredient in VASOSTRICT is vasopressin. There are nine drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the vasopressin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Vasostrict

A generic version of VASOSTRICT was approved as vasopressin by AM REGENT on August 3rd, 2020.

  Sign Up

Drug patent expirations by year for VASOSTRICT
Drug Prices for VASOSTRICT

See drug prices for VASOSTRICT

Recent Clinical Trials for VASOSTRICT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
La Jolla Pharmaceutical CompanyPhase 4
University of New MexicoPhase 4
National Center for Advancing Translational Science (NCATS)Phase 4

See all VASOSTRICT clinical trials

Paragraph IV (Patent) Challenges for VASOSTRICT
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VASOSTRICT Injection vasopressin 20 units/100 mL 204485 1 2022-12-20
VASOSTRICT Injection vasopressin 40 units/100 mL and 60 units/100 mL 204485 1 2022-02-28
VASOSTRICT Injection vasopressin 200 units/10 mL 204485 1 2018-06-29
VASOSTRICT Injection vasopressin 20 units/mL, 1 mL 204485 1 2018-03-23

US Patents and Regulatory Information for VASOSTRICT

VASOSTRICT is protected by fourteen US patents.

Patents protecting VASOSTRICT

Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Vasopressin formulations for use in treatment of hypotension
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Operations VASOSTRICT vasopressin SOLUTION;INTRAVENOUS 204485-002 Dec 17, 2016 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Endo Operations VASOSTRICT vasopressin SOLUTION;INTRAVENOUS 204485-004 Apr 15, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Endo Operations VASOSTRICT vasopressin SOLUTION;INTRAVENOUS 204485-006 Apr 12, 2023 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.